Sarepta Reports Preclinical SRP-1003 Data Showing Up to ~80% DMPK Knockdown

Sarepta reported dose-dependent DMPK knockdown in the nucleus and cytoplasm, with MBNL mis-splicing correction. SRP-1003 is in an ongoing Phase 1/2 trial, with results expected later this year.